Autolus Therapeutics AUTL
NASDAQ AUTL
$1.78 -0.07 (-3.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

Autolus Therapeutics (AUTL) Gains from Sales and Divestitures (2021 - 2025)

Updated

Autolus Therapeutics (AUTL) posted Gains from Sales and Divestitures of -$11,000 for Q4 2025.

Analysis

Autolus Therapeutics (AUTL) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends

For FY2025, Autolus Therapeutics' Gains from Sales and Divestitures came in at -$14,000.

  • In prior years, Autolus Therapeutics' Gains from Sales and Divestitures was -$223,000 in FY2024, -$3.79 million in FY2023, -$515,000 in FY2022 and -$672,000 in FY2021.
  • The Q4 2025 figure stands as the lowest quarterly Gains from Sales and Divestitures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Autolus Therapeutics 631.98 Mn -692.11 Mn 25.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -11,000.00
Mar 31, 2025 -3,000.00
Sep 30, 2024 -223,000.00
Dec 31, 2023 21,000.00
Jun 30, 2023 -23,000.00
Mar 31, 2023 -3.79 Mn
Dec 31, 2022 -515,000.00
Mar 31, 2021 -672,000.00
API Access

Autolus Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=AUTL&period=max&api_key=YOUR_API_KEY